Biogen To Gain Rights To BAT1806 From Bio-Thera - Quick Facts

Biogen Inc. (BIIB) and Bio-Thera Solutions have reached an agreement to develop, manufacture and commercialize BAT1806, a phase 3 clinical stage anti-interleukin-6 receptor monoclonal antibody that is a proposed biosimilar referencing ACTEMRA (tocilizumab). Biogen will gain exclusive regulatory, manufacturing and commercial rights to BAT1806 in all countries excluding China.

Biogen will make an upfront payment of $30 million to Bio-Thera Solutions, contingent upon Bio-Thera Solutions' phase 3 for BAT1806 achieving satisfactory results. Bio-Thera Solutions will be eligible to receive potential milestone payments on achieving commercial milestones. Biogen will also pay Bio-Thera Solutions tiered royalties.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
American Airlines canceled hundreds of flights this weekend and plans to cut more through at least mid-July due to bad weather and staffing shortages, multiple reports said. The shortage of flights come as demand is increasing heavily in the United States with reducing coronavirus cases benefited mainly by increased vaccination. Chinese HR firm 51job, Inc. (JOBS) announced Monday that it has entered into a definitive Agreement and Plan of Merger with Garnet Faith Limited, pursuant to which, and subject to the terms and conditions thereof, Garnet Faith will merge with and into 51job, with 51job being the surviving company, in... Priceline, affiliated to Booking Holdings Inc., is launching Fourth of July Freedom sale with bigger savings on flights, hotels and rental cars for the upcoming summer travel season. The company, which offers exclusive discounts on hotels, flights, alternative accommodations, rental cars, cruises and packages, said the two-week Freedom Sale will feature special discounts and promotions.
Follow RTT